Abstract:Objective: To investigate the mutation of the KRAS/NRAS/BRAF/PIK3CA gene and its relationship with clinicopathological features in colorectal cancer (CRC). Methods: The surgical resection specimens of 91 patients with primary CRC from 2012 to 2016 in Shanghai Fifth People's Hospital affiliated with Fudan University were collected for retrospective analysis. Detecting mutations in the KRAS/NRAS/BRAF/PIK3CA genes were confirmed by an amplification-refractory mutation system (ARMS). Immunohistochemistry (IHC) was conducted to confirm the expression of KRAS, NRAS, BRAF, and PIK3CA proteins.Results: Among 91 CRC patients, the mutation rates of the KRAS, NRAS, BRAF, and PIK3CA genes were 40.7% (37/91), 4.4% (4/91), 3.3% (3/91) and 2.2% (2/91), respectively. The KRAS/PIK3CA double mutation rate was 2.2% (2/91), and the KRAS/NRAS double mutation rate was 1.1% (1/91). The mutation rate of the BRAF gene in poorly differentiated CRC patients was significantly higher than that in moderately to well-differentiated patients (P < 0.05). PIK3CA gene mutation was significantly different between primary tumour sites (P < 0.05). The mutation rate of the KRNS/NRAS/BRAF/PIK3CA genes in patients with lymph node metastasis (78.3%, 18/23) was significantly higher than that in patients without lymph node metastasis (45.6%, 31/68) (P < 0.05). No significant differences in immunohistochemical expression between KRAS-, NRAS-, BRAF-, and PIK3CA-mutant patients and nonmutated patients were confirmed (P>0.05). Conclusions: KRAS mutation is the most common mutated gene in CRC patients. PIK3CA mutation is often accompanied by KRAS mutation, and EGFR treatment resistance in KRAS wild-type patients may be caused by PIK3CA gene mutation. Simultaneous detection of KRAS/NRAS/BRAF/PIK3CA gene mutations helps to develop the most accurate treatment for CRC patients. KRAS/NRAS/BRAF/PIK3CA gene mutations were associated with several clinicopathological features in this group of CRC patients, but more cases need to be confirmed by further studies. Gene mutations in CRC patients are best detected by DNA sequencing or ARMS methods.Funding Information: This work was supported by the High-level Professional Physician Training Program of Minhang District, Shanghai City (No. 2020MZYS10).Declaration of Interests: None.Ethics Approval Statement: The study was approved by the Ethical Committee of Shanghai Fifth People's Hospital, Fudan University (No. 2021071). Patients did not need to give informed consent because anonymous data were used in the analysis, which were obtained after each patient's written consent to treatment.

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Survival and Prognosis Analyses of Concurrent PIK3CA Mutations in EGFR Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.

KRAS and PIK3CA Bi-Mutations Predict a Poor Prognosis in Colorectal Cancer Patients: A Single-Site Report.

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Pik3ca Mutation Analysis in Chinese Patients with Solid Tumors.

PIK3CA Mutation in Chinese Patients with Lung Squamous Cell Carcinoma

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

BRAF/ KRAS and PIK3CA mutation characteristics and clinical significance in primary small cell lung caner

Frequency of Pik3ca Mutations in Chinese Her2+Metastatic Breast Cancer Patients and Association with Clinical Benefit to Lapatinib and Capecitabine Treatment.

The Spectrum, Tendency and Predictive Value of <i>PIK3CA</i> Mutation in Chinese Colorectal Cancer Patients

The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients

Preliminary Analysis of Genomic Profiling of Small Cell Lung Cancer in Chinese Population Revealed Frequent PIK3CA Hotspot Mutations.

PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer

Clinicopathological Characteristics and Prognostic Analysis of PIK3CA Mutation in Breast Cancer Patients in Northwest China

A Study on the Relationship Between KRAS, NRAS, BRAF and PIK3CA Gene Mutations and Clinicopathological Features in Patients with Colorectal Cancer

Frequency, Characterization, and Prognostic Analysis of PIK3CA Gene Mutations in Chinese Esophageal Squamous Cell Carcinoma.